Although they aren't a massive market in terms of potential patient, the treatment cost for rare cancer are usually expensive though so IMU can still generate very good revenue from the cholangiocarcinoma and DLBCL market to have a $1B MC valuation with the normal EPS ratio for commercialise biotech stock but IMU will need to bring the drug to market themselves. Maybe @mrdingo's 15c was always correct lol.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)